NAVCO Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Net Income	-0.07	-0.08	-1.72	-2.15	-0.47	-0.53
Depreciation & Amortization	0	0	0.03	0.04	0.04	0.03
Asset Writedown & Restructuring Costs	-	-	0.11	-	-	-
Stock-Based Compensation	-	-	0.78	0.27	-	-
Other Operating Activities	0.01	0.01	0.01	0.68	0.01	0.01
Change in Inventory	-	-	0	0	0.01	-0.01
Change in Accounts Payable	0.02	0.02	-0.04	-0.07	0.12	0.07
Change in Other Net Operating Assets	0.02	0.03	0.58	-0.56	0.28	0.17
Operating Cash Flow	-0.02	-0.02	-0.25	-1.78	-0	-0.24
Capital Expenditures	-	-	-	-	-	-0.07
Investing Cash Flow	-	-	-	-	-	-0.07
Short-Term Debt Issued	-	0.02	0.05	-	0.04	0.02
Total Debt Issued	0.02	0.02	0.05	-	0.04	0.02
Short-Term Debt Repaid	-	-	-	-0.05	-0.02	-
Long-Term Debt Repaid	-	-0	-0.02	-0.02	-0.02	-0.02
Total Debt Repaid	-	-0	-0.02	-0.07	-0.04	-0.02
Net Debt Issued (Repaid)	0.02	0.02	0.03	-0.07	0	0
Issuance of Common Stock	-	-	-	2.11	-	0.12
Other Financing Activities	-	-	-	-0.03	-	-
Financing Cash Flow	0.02	0.02	0.03	2.01	0	0.12
Net Cash Flow	-0	-0	-0.23	0.23	-0	-0.19
Free Cash Flow	-0.02	-0.02	-0.25	-1.78	-0	-0.31
Free Cash Flow Margin	-	-	-	-	-7.72%	-2027.27%
Free Cash Flow Per Share	-	-	-0.01	-0.06	-	-0.02
Levered Free Cash Flow	0.05	0.05	0.33	-0.5	-0.44	-
Unlevered Free Cash Flow	0.06	0.05	0.34	-0.49	-0.43	-
Change in Working Capital	0.04	0.05	0.54	-0.62	0.4	0.24

Source: S&P Capital IQ. Standard template. Financial Sources.